GH Research PLC
GHRSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, GH Research PLC focuses on Biotechnology services and products. GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company carries a $1.91B market cap, placing it firmly in the small-cap category. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Market Cap
$1.91B
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
-15.02
EPS (TTM)
$-0.99
EPS (Fwd)
$-1.85
ROE
-18.8%
ROA
-13.0%
Cash
$362.6M
Total Debt
$360,000
Free CF
-$36.5M
52W Change
110.4%
Annual Financials
Cash vs Debt
Where GHRS stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, GHRS finished 46.67% above its 150-day moving average ($20.44) and 59.38% above its 200-day moving average ($18.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GHRS overbought or oversold?
At the August 18, 2026 close, GHRS's RSI(14) was 60.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
GH Research PLC holds $362.6M in cash against $360K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$36.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -18.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for GH Research PLC and its sector.